TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01326689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246
Description: Rescue medication at an optimal dose, which is determined by dose titration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01772212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Reference product
Study: NCT01131923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg
Study: NCT00671502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR
Description: 700 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR
Description: 500 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03736291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
Study: NCT01106898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02466113

Intervention type: OTHER
Group type: OTHER
Intervention: A classic stratified tool
Description: Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
Study: NCT00999791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study: NCT00732355

Intervention type: DEVICE
Intervention: Syph-Check POC
Description: Rapid membrane test for syphilis antibodies

Intervention type: DEVICE
Intervention: Syph-Check POC
Description: Rapid membrane test for syphilis antibodies
Study: NCT03313284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT
Description: RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT + IH
Description: RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study: NCT04583202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to placebo
Description: Patients are exposed to a placebo for 4h in the Alyatec EEC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to allergen
Description: Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
Study: NCT00825396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 150 days
Study: NCT01437176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new type of intramedullary nail
Description: This is a new fixation treat for intertrochanteric fracture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intramedullary nail of PFNA
Description: It was used very common in treat with intertrochanteric fracture.
Study: NCT03255538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure - 25%
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure + 25%
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
Study: NCT03417362

Intervention type: OTHER
Group type: OTHER
Intervention: Animation
Description: 3 minute video describing and explaining early medical abortion, followed by questionnaire
Study: NCT01688843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INGEVITY lead
Study: NCT01253265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT00769717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness-Centered (HUGS)
Description: A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight-Centered (LEARN)
Description: The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
Study: NCT03287570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cettum
Description: The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional indirect moxibustion
Description: The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The patients in this group maintain the usual treatment and self-care.
Study: NCT00435812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV and/or Placebo
Description: Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections on Week 0, Week 4, and Week 24
Study: NCT03689803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: gastric bypass
Study: NCT02649907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional stimulation via different testmeals
Description: nutritional stimulation of hormonal response through different testmeals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: nutritional counseling for healthy eating behaviour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula diet
Description: formula diet to help weight loss
Study: NCT00640445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
Study: NCT04529837

Intervention type: OTHER
Intervention: Gauze
Description: placement of gauze
Study: NCT00640445

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Writing
Description: Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
Study: NCT02671994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G8 screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Study: NCT01778829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP ventilation mode
Description: Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV ventilation mode
Description: Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
Study: NCT01306357

Intervention type: DRUG
Intervention: Somatropin
Description: 4 mg or 10 mg delivered by needle-free device
Study: NCT03838822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cofactors
Description: Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
Study: NCT01382979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College
Description: Online course for college freshmen.
Study: NCT00711802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Study: NCT02425800

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of tissue samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00023543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, fat-restricted
Description: Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Rigorous, stepped care approach to reach 150 min/week of physical activity.
Study: NCT00227162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
Study: NCT00751283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRST Peripheral Catheter System
Description: Treatment to dilate stenoses and reduce plaque in treated vessels
Study: NCT00227162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
Study: NCT00882908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
Study: NCT00227162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
Study: NCT03444519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
Study: NCT04529837

Intervention type: OTHER
Intervention: No gauze
Description: no gauze
Study: NCT01307111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Study: NCT04573907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Levothyroxine 100 mcg
Description: Administration of a 600 mcg levothyroxine dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eutirox 100 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT00681655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (saline vehicle) infused for 2.8 hour long session.
Study: NCT04034407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Damage control surgery
Description: All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Damage control surgery
Description: All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis.
Study: NCT04234321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic fibroblast growth factor
Description: Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangfuxin Liquid
Description: Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: 0.9% Normal saline,20ml / 100cm2 / time,three times a day.
Study: NCT01776775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal binder
Description: The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position.
Study: NCT01209364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane is a device, methylprednisolone in a drug
Description: single intraarticular injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane is a device, methylprednisolone in a drug
Description: single intraarticular injection
Study: NCT03938584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
Study: NCT04476433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ten Vida (10Vida)
Description: 10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
Study: NCT03228589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic strain
Description: 8 weeks of treatment with probiotic strain

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of treatment
Study: NCT04394104

Intervention type: OTHER
Intervention: Survey
Description: No intervention is being administered.
Study: NCT01172457

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Epiduroscopy with oxygen therapy
Description: Patients in this group will receive 30 mL of oxygen by epiduroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epiduroscopy with ozone therapy
Description: Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
Study: NCT00506701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 40 mg tablet
Study: NCT01604655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary CT Angiography
Description: CCTA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Test
Description: Stress Test
Study: NCT04097496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act Out! Intervention
Description: Data included in the description of the intervention arm.
Study: NCT03546504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procedure alteration and occupational therapy
Description: Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
Study: NCT02130986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin level
Description: A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Results of procalcitonin (PCT) level to treating clinician
Description: In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide procalcitonin guideline to treating clinician
Description: Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Visit
Description: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Visit
Description: We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
Study: NCT03698175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three good things exercise
Description: Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo exercise
Description: Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.